학술논문

Guselkumab as a switching strategy after anti-TNFα, anti-IL17, or anti-IL12/23 therapies in moderate-to-severe psoriasis
Document Type
Article
Source
In: Dermatologic Therapy. (Dermatologic Therapy, October 2022, 35(10))
Subject
Language
English
ISSN
15298019
13960296